Gene · 2248
Papers2,103
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 2,103
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| REVIEW OF THE BLADDER CANCER MOLECULAR CLASSIFICATION PROPOSED: A NEW ERA - NEW TAXONOMY. | Acta Clin Croat | 2022 | 35282497 | PubTator, text mining | PubMed |
| Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review. | Ann Transl Med | 2022 | 35282060 | PubTator, text mining | PubMed |
| Analysis of transcript-wide profile regulated by microsatellite instability of colorectal cancer. | Ann Transl Med | 2022 | 35280417 | PubTator, text mining | PubMed |
Serum cystatin C, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, klotho and fibroblast growth factor-23 in the early prediction of acute kidney injury associated with sepsis in a Chinese emergency cohort study. | Eur J Med Res | 2022 | 35272698 | PubTator, text mining | PubMed |
| Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets. | Cancers (Basel) | 2022 | 35267539 | PubTator, text mining | PubMed |
| Clonality, Mutation and Kaposi Sarcoma: A Systematic Review. | Cancers (Basel) | 2022 | 35267506 | PubTator, text mining | PubMed |
| Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. | Cancers (Basel) | 2022 | 35267459 | PubTator, text mining | PubMed |
| Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC. | Signal Transduct Target Ther | 2022 | 35260570 | PubTator, text mining | PubMed |
| TraSig: inferring cell-cell interactions from pseudotime ordering of scRNA-Seq data. | Genome Biol | 2022 | 35255944 | PubTator, text mining | PubMed |
| Genetic overlap between temporomandibular disorders and primary headaches: A systematic review. | Jpn Dent Sci Rev | 2022 | 35242249 | PubTator, text mining | PubMed |
| Longitudinal Imaging of the Skull Base Synchondroses Demonstrate Prevention of a Premature Ossification After Recifercept Treatment in Mouse Model of Achondroplasia. | JBMR Plus | 2022 | 35229060 | PubTator, text mining | PubMed |
| Elucidating Sulfide Activation Mode in Metal-Catalyzed Sulfoxidation Reactivity. | Inorg Chem | 2022 | 35226481 | PubTator, text mining | PubMed |
| PTK7, a Catalytically Inactive Receptor Tyrosine Kinase, Increases Oncogenic Phenotypes in Xenograft Tumors of Esophageal Squamous Cell Carcinoma KYSE-30 Cells. | Int J Mol Sci | 2022 | 35216506 | PubTator, text mining | PubMed |
| Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures. | Int J Mol Sci | 2022 | 35216378 | PubTator, text mining | PubMed |
| The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes? | Front Immunol | 2022 | 35211123 | PubTator, text mining | PubMed |
| Organotypic Epithelial Raft Cultures as a Three-Dimensional In Vitro Model of Merkel Cell Carcinoma. | Cancers (Basel) | 2022 | 35205840 | PubTator, text mining | PubMed |
| Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer. | Open Biol | 2022 | 35193394 | PubTator, text mining | PubMed |
| Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib. | NPJ Breast Cancer | 2022 | 35181666 | PubTator, text mining | PubMed |
| FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor. | Genes Chromosomes Cancer | 2022 | 35170141 | PubTator, text mining | PubMed |
| Demystifying DPP III Catalyzed Peptide Hydrolysis-Computational Study of the Complete Catalytic Cycle of Human DPP III Catalyzed Tynorphin Hydrolysis. | Int J Mol Sci | 2022 | 35163780 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2248/papers?page=25